Best Biochemical Supplier Ottawa Near Me

4worldlovers: Together, our commitment to bettering society, the environment, and the economy is unwavering. We share our members’ stories with decision-makers at the federal and provincial levels to help shape public policy that supports innovation, investment, sustainability, jobs, and the environment.

Learn about CIAC’s made-in-Canada environmental, social and governance initiative, Responsible Care.

For nearly 40 years, Responsible Care has led the journey towards safe, responsible and sustainable chemical manufacturing. Take a moment and read this interactive report that outlines our members’ accomplishments throughout the 2022 calendar year.


Take a look back at 2022 and read about the challenges, events, and many accomplishments from the chemistry and plastics sector.

In 2019, the federal government committed to the goal of net-zero emissions for all of Canada by 2050 and in 2020, the Net-Zero Emissions Accountability Act came

Into force. Achieving this will require chemistry-based solutions, which includes the plastics sector.

Products Canadians use every day are made with chemistry and plastics

CIAC hosts Responsible Care workshops, Board and Committee meetings in Toronto

With a modernized Environmental Protection Act, Canada continues to lead the way in chemicals management

4worldlovers: At Turnstone, our mission is to develop new medicines to treat and cure patients with solid tumors.

Solid tumors present a major burden to society, with high mortality and poor outcomes associated with more advanced disease. Approved immunotherapies represent a significant advancement in the treatment of solid tumors, but many patients either do not respond or experience relapsed disease following an initial response. We believe the most significant challenge to creating curative immunotherapies in these patients is the low numbers of T cells that can recognize and attack the tumor, which we refer to as tumor‑reactive T cells.

To address this problem, we are pioneering a differentiated approach to tumor infiltrating lymphocytes, or TILs. We are developing next-generation TIL therapies by selecting the most potent (meaning able to mediate an anti-tumor response) and tumor-reactive T cells, which we refer to as Selected TILs. We are developing next-generation TIL therapies for potential treatment across multiple solid tumors.